drugset / Trial / NCT00570713
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.
Timeline
- Start
- 2007-12
- Primary completion
- 2009-12
- Completion
- 2009-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amatuximab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |